Abstracts tagged "remission and rheumatoid arthritis (RA)"

Abstract Number: 867 • 2018 ACR/ARHP Annual Meeting
An MRI Guided Treat-to-Target Strategy in Rheumatoid Arthritis Patients in Clinical Remission Improved MRI Inflammation but Not Damage Progression – Results from the Imagine-RA Randomized Controlled Trial
Signe Møller-Bisgaard¹, Kim Hørslev-Petersen², Bo Jannik Ejbjerg³, Daniel Glinatsi⁴, Merete Lund Hetland¹, Lykke Ørnbjerg¹, Jakob M. Møller⁵, Mikael Boesen⁶, Robin Christensen⁷, Kristian Stengaard-Pedersen⁸, Ole Rintek Madsen⁹, Bente Jensen¹⁰, Jan Alexander Villadsen¹¹, Ellen-Margrethe Hauge⁸, Philip Bennett¹², Oliver Hendricks², Karsten Asmussen¹³, Marcin Ryszard Kowalski¹⁴, Hanne Lindegaard¹⁵, Sabrina Mai Nielsen⁷, Henning Bliddal¹⁶, Niels Steen Krogh¹⁷, Torkell Ellingsen¹⁵, Agente Nielsen¹⁸, Lone Balding¹⁹, Anne Grethe Jurik²⁰, Henrik S Thomsen¹⁹ and Mikkel Østergaard²¹, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ²King Christian 10th Hospital for Rheumatic Diseases, University of Southern Denmark, Institute of Regional Health Research, Graasten, Denmark, ³Department of Rheumatology, Zealand University Hospital, Køge, Denmark, ⁴Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark, ⁵Dept. of Radiology, Copenhagen University Hospitals, Herlev and Gentofte, Copenhagen, Denmark, ⁶Department of Radiology, Bispebjerg-Frederiksberg Hospital, Copenhagen, Copenhagen, Denmark, ⁷Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg, Denmark, ⁸Department of Rheumatology, Aarhus University Hospital, Department of Clinical Medicine, Aarhus, Denmark, ⁹Department of Rheumatology, Copenhagen University Hospital, Herlev and Gentofte, Hellerup, Denmark, ¹⁰Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, Copenhagen, Denmark, ¹¹Department of Rheumatology, Silkeborg Hospital, Silkeborg, Denmark, ¹²Department of Rheumatology, Copenhagen University Hospital, Herlev and Gentofte, Copenhagen, Denmark, ¹³Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ¹⁴Department of Rheumatology, Sygehus Vendsyssel, Hjørring, Hjørring, Denmark, ¹⁵Department of Rheumatology, Odense University Hospital, Odense, Denmark, ¹⁶The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ¹⁷The DANBIO Registry, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ¹⁸Department of Radiology, Silkeborg Hospital, Silkeborg, Denmark, ¹⁹Department of Radiology, Copenhagen University Hospital Herlev and Gentofte, Copenhagen, Denmark, ²⁰Department of Radiology, Aarhus University Hospital, Aarhus, Denmark, ²¹Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup Copenhagen Center for Arthritis Research, Copenhagen, Denmark
Background/Purpose: Magnetic Resonance Imaging (MRI) bone marrow edema (BME)/osteitis and MRI synovitis have been identified as predictors of structural damage progression in rheumatoid arthritis RA1,2.…
Abstract Number: 881 • 2018 ACR/ARHP Annual Meeting
Association of Comorbidities with DAS28 Disease Status and Remission in Race/Ethnic Groups with Rheumatoid Arthritis
Sharon Dowell¹, Rodolfo Perez-Alamino², Christopher J. Swearingen³, Gail S. Kerr⁴ and Yusuf Yazici⁵, ¹Internal Medicine, Howard University, Washington, DC, ²Rheumatology Department, Hospital de Clínicas Pte. Dr. Nicolás Avellaneda, Tucumán, Argentina, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Rheumatology, Washington DC VAMC and Georgetown and Howard University, Washington, DC, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Racial/ethnic disparities in comorbidity (CM) in rheumatoid arthritis (RA) may confound treatment and outcomes. Rheumatic Disease Comorbidity Index (RDCI) is a validated tool predicting…
Abstract Number: 1451 • 2018 ACR/ARHP Annual Meeting
The Value of Adding MRI to a Clinical Treat-to-Target Strategy in Rheumatoid Arthritis Patients in Clinical Remission: Clinical and Radiographic Outcomes from the Imagine-RA Randomized Controlled Trial
Signe Møller-Bisgaard¹, Kim Hørslev-Petersen², Bo Jannik Ejbjerg³, Merete Lund Hetland¹, Daniel Glinatsi⁴, Lykke Ørnbjerg¹, Jakob M. Møller⁵, Mikael Boesen⁶, Robin Christensen⁷, Kristian Stengaard-Pedersen⁸, Ole Rintek Madsen⁹, Bente Jensen¹⁰, Jan Alexander Villadsen¹¹, Ellen-Margrethe Hauge⁸, Philip Bennett¹², Oliver Hendricks², Karsten Asmussen¹³, Marcin Ryszard Kowalski¹⁴, Hanne Lindegaard¹⁵, Sabrina Mai Nielsen⁷, Henning Bliddal¹⁶, Niels Steen Krogh¹⁷, Torkell Ellingsen¹⁵, Agente Nielsen¹⁸, Lone Balding⁵, Anne Grethe Jurik¹⁹, Henrik S Thomsen⁵ and Mikkel Østergaard²⁰, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ²King Christian 10th Hospital for Rheumatic Diseases, University of Southern Denmark, Institute of Regional Health Research, Graasten, Denmark, ³Department of Rheumatology, Zealand University Hospital, Køge, Denmark, ⁴Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark, ⁵Department of Radiology, Copenhagen University Hospital Herlev and Gentofte, Copenhagen, Denmark, ⁶Department of Radiology, Bispebjerg-Frederiksberg Hospital, Copenhagen, Copenhagen, Denmark, ⁷Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg, Denmark, ⁸Department of Rheumatology, Aarhus University Hospital, Department of Clinical Medicine, Aarhus, Denmark, ⁹Department of Rheumatology, Copenhagen University Hospital, Herlev and Gentofte, Hellerup, Denmark, ¹⁰Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, Copenhagen, Denmark, ¹¹Department of Rheumatology, Silkeborg Hospital, Silkeborg, Denmark, ¹²Department of Rheumatology, Copenhagen University Hospital, Herlev and Gentofte, Copenhagen, Denmark, ¹³Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ¹⁴Department of Rheumatology, Sygehus Vendsyssel, Hjørring, Hjørring, Denmark, ¹⁵Department of Rheumatology, Odense University Hospital, Odense, Denmark, ¹⁶The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ¹⁷The DANBIO Registry, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ¹⁸Department of Radiology, Silkeborg Hospital, Silkeborg, Denmark, ¹⁹Department of Radiology, Aarhus University Hospital, Aarhus, Denmark, ²⁰Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup Copenhagen Center for Arthritis Research, Copenhagen, Denmark
Background/Purpose: Targeting MRI remission in rheumatoid arthritis (RA) patients in clinical remission may improve clinical outcome and halt joint damage progression. The purpose of the…
Abstract Number: 1518 • 2018 ACR/ARHP Annual Meeting
Baricitinib and Tofacitinib in Real Life – Does Obesity Impact Response to Janus Kinase Inhibitor Therapy in Rheumatoid Arthritis?
Yvette Meißner¹, Lisa Baganz¹, Matthias Schneider², Ilka Schwarze³, Martin Feuchtenberger⁴, Angela Zink⁵ and Anja Strangfeld⁶, ¹Programme Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Department of Rheumatology & Hiller Research Unit, Medical Faculty, University Hospital, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ³Praxis internistische Rheumatologie, Leipzig, Germany, ⁴Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ⁵Epidemiology Unit / Rheumatology and Clinical Immunology, German Rheumatism Research Centre (DRFZ) / Charité University Hospital, Berlin, Germany, ⁶Epidemiology, German Rheumatism Research Center, Berlin, Germany
Background/Purpose: The influence of obesity on treatment response of tumor necrosis factor inhibitors in patients with rheumatoid arthritis (RA) is described in literature, but data…
Abstract Number: 2468 • 2018 ACR/ARHP Annual Meeting
Window or No Window? Earlier Is Better When Treating Rheumatoid Arthritis
Sytske Anne Bergstra¹, Joy A. van der Pol², Nagmeh Riyazi³, Yvonne P. Goekoop-Ruiterman³, Arvind Chopra⁴, José António P. da Silva⁵, Pit J.S.M. Kerstens⁶, Willem F. Lems⁷, S. Tsonaka⁸, Tom W.J. Huizinga¹ and Cornelia F. Allaart¹, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³HAGA Hospital, The Hague, Netherlands, ⁴Center for Rheumatic Diseases, Pune, India, ⁵Department of rheumatology, Centro Hospitalar e Universitário de Coimbra (SRHUC), Coimbra, Portugal, ⁶Amsterdam Rheumatology and Immunology Center | Reade, Amsterdam, Netherlands, ⁷Department of Rheumatology, VU Medical Center, Amsterdam, Netherlands, ⁸Department of Medical Statistics and Bioinformatics, LUMC, Leiden, Netherlands
Background/Purpose: Previous reports on a window of opportunity (WOO) in rheumatoid arthritis (RA) may be related to the use of slow acting csDMARDs. We investigated…
Abstract Number: 2953 • 2018 ACR/ARHP Annual Meeting
Disappearance of Autoantibodies in RA: Does It Occur with Current Treatment Strategies? a Long-Term Follow-up Study in Patients That Achieved DMARD-Free Sustained Remission
Debbie M. Boeters¹, Leonie E. Burgers¹, René E.M. Toes¹ and Annette H.M. van der Helm-van Mil^1,2, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Disease modifying antirheumatic drug (DMARD)-free sustained remission, the sustained absence of arthritis after cessation of all DMARD-therapy, is increasingly achievable with current treatment strategies.…
Abstract Number: 548 • 2018 ACR/ARHP Annual Meeting
Persistence in Low Disease Activity or Remission with Etanercept Monotherapy in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
Dimitrios A. Pappas¹, Ying Shan², Tamara Lesperance³, Sabrina Rebello², Elaine Karis⁴, Greg Kricorian⁴, Winnie Hua⁵, Neil A. Accortt⁴ and Scott Stryker⁴, ¹Corrona LLC, Waltham, MA, ²Corrona, LLC, Southborough, MA, ³DOCS Global, Inc., North Wales, PA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Corrona, LLC, Waltham, MA
Background/Purpose: Monotherapy with etanercept (ETN) may be a viable therapeutic option for maintenance of patients with rheumatoid arthritis (RA) who prefer to eliminate potential burdens…
Abstract Number: 549 • 2018 ACR/ARHP Annual Meeting
Unmet Treat-to-Target Goals with Available Targeted Immunomodulators in the Management of Rheumatoid Arthritis: Real World Evidence from the Corrona Registry
Dimitrios A. Pappas^1,2, Namita Tundia³, Ying Shan², Heather J Litman² and Joel Kremer⁴, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³AbbVie Inc., North Chicago, IL, ⁴Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: Targeted immunomodulators (TIMs) have revolutionized the therapy of RA and made low disease activity (LDA) a realistic goal for patients. Given the multiple therapy…
Abstract Number: 562 • 2018 ACR/ARHP Annual Meeting
Low Inflammation on Magnetic Resonance Imaging in Patients with Rheumatoid Arthritis That Achieved Sustained Clinical Remission on Adalimumab
Paul Emery¹, Gerd R. Burmester², Esperanza Naredo³, Ivan Lagunes Galindo⁴, Ying Zhang⁵, Xin Wang⁵, Maja Hojnik⁶ and Philip G. Conaghan⁷, ¹University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ²Charité-University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ³Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie, North Chicago, IL, ⁶AbbVie, Ljubljana, Slovenia, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: ACR and EULAR recommend bDMARD tapering in patients (pts) with rheumatoid arthritis (RA) who achieved stable clinical remission. Yet, there are limited systematically collected…
Abstract Number: 584 • 2018 ACR/ARHP Annual Meeting
Changes in CD4+ T and B Cell Profile As Indicator of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis
Borja Hernández-Breijo^1,2, Israel Gañán-Nieto³, Cristina Sobrino³, Victoria Navarro-Compán¹, Ana Martínez^1,2, Carlota García-Hoz³, Javier Bachiller³, María Gema Bonilla Hernán^1,4, Garbiñe Roy⁵, Mónica Vázquez³, Alejandro Balsa^1,6, Luisa María Villar³, Dora Pascual-Salcedo¹, Eulalia Rodríguez-Martín³ and Chamaida Plasencia^1,4, ¹Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain, ²Immunology. La Paz University Hospital, Madrid, Spain, ³Immuno-Rheumatology research group, IRYCIS. Ramón y Cajal University Hospital, Madrid, Spain, ⁴Rheumatology, La Paz University Hospital, Madrid, Spain, ⁵Immunology. Ramón y Cajal University Hospital and IRYCIS, Madrid, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: TNF inhibitors (TNFi) are widely used for the treatment of rheumatoid arthritis (RA). This study aims to analyse the profile of peripheral blood mononuclear…
Abstract Number: 590 • 2018 ACR/ARHP Annual Meeting
Advances in Therapeutic Management with First Biological Therapy in Rheumatoid Arthritis throughout 15 Years
Patricia Bogas¹, Chamaida Plasencia², Victoria Navarro-Compán³, Diego Benavent², Gabriela Gonzalez², María Gema Bonilla Hernán², Irene Monjo¹ and Juan Molina¹, ¹Rheumatology, Rheumatology, La Paz University Hospital, Madrid, Spain, ²Rheumatology, La Paz University Hospital, Madrid, Spain, ³Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain
Background/Purpose: In the last two decades the treatment in patients with rheumatoid arthritis (RA) has undergone major advances, especially due to the appearance of new…
Abstract Number: 614 • 2018 ACR/ARHP Annual Meeting
Disease Activity One Year after Addition of Bucillamine or Sulfasaladine to Methotrexate in Japanese Patients with Rheumatoid Arthritis : Propensity Score Analysis
Genki Kidoguchi¹ and Kenichiro Tokunaga², ¹General internal medicine, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan, ²Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan
Background/Purpose: Bucillamine (BUC) is a small-molecule disease-modifying antirheumatic drug (DMARD) developed in Japan. The efficacy of combination therapy with BUC and methotrexate (MTX) has been demonstrated…
Abstract Number: 348 • 2017 ACR/ARHP Annual Meeting
The Impact of Rheumatoid Arthritis-Sustained Remission on Patient´s Reported Outcomes Differs Accordingly to Each Particular Outcome
Irazú Contreras-Yáñez¹, Guillermo Guaracha², César Sifuentes-Cantú³ and Virginia Pascual-Ramos⁴, ¹Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Instituto Nacional de Ciencias Médicas y Nutrició, Mexico City, Mexico
Background/Purpose: Sustained remission (SR) is the most desirable status in patients with rheumatoid arthritis (RA). For adoption by patients, SR should reflect symptom´s resolution and…
Abstract Number: 414 • 2017 ACR/ARHP Annual Meeting
Multi-Biomarker Disease Activity and Autoantibody Status Lead to Cost Effective Tapering Algorithms in Rheumatoid Arthritis Patients in Sustained Remission
Melanie Hagen¹, Matthias Englbrecht², Judith Haschka³, Michaela Reiser⁴, Arnd Kleyer⁵, Axel J. Hueber⁶, Bernhard Manger⁷, Camille Figueiredo⁸, Jayme Fogagnolo Cobra⁹, Hans-Peter Tony¹⁰, Stefanie Finzel¹¹, Stefan Kleinert¹², Joerg Wendler¹³, Florian Schuch¹³, Monika Ronneberger¹³, Martin Feuchtenberger¹⁴, Martin Fleck^15,16, Karin Manger¹⁷, Matthias Schmitt-Haendle¹⁸, H.-M. Lorenz¹⁹, HG Nüßlein²⁰, Rieke Alten²¹, Joerg C. Henes²², Klaus Krüger²³, Georg Schett² and Juergen Rech²⁴, ¹University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ³Medical Department II, St. Vincent Hospital, the VINFORCE Study Group, Academic Teaching Hospital of Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁴Department of Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Dept of Medicine 3, Rheumatology and Clinical Immunology, Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, ⁶Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁷Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁸Institution de Rheumatologia, Sao Paolo, Brazil, ⁹Instituto de Reumatologia de Sao Paolo, Sao Paolo, Brazil, ¹⁰Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany, ¹¹University of Freiburg, Freiburg, Germany, ¹²Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Germany, ¹³Schwerpunktpraxis Rheumatologie, Erlangen, Germany, ¹⁴Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ¹⁵Department of Rheumatology and Clinical Immunology, Asklepios Medical Center Bad Abbach, Bad Abbach, Germany, ¹⁶Internal Medicine I, University Medical Center of Regensburg, Regensburg, Germany, ¹⁷Rheumatology Practice Bamberg, Bamberg, Germany, ¹⁸Rheumatology Practice, Bayreuth, Germany, Bayreuth, Germany, ¹⁹Rheumatology, University Heidelberg, Heidelberg, Germany, ²⁰Rheumatology Practice Nuremberg, Nuremberg, Germany, ²¹Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ²²Department of Internal Medicine II, Division of Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ²³Praxiszentrum St.Bonifatius, Munich, Germany, ²⁴Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany
Background/Purpose: Achieving remission is the ultimate treatment goal in patients with rheumatoid arthritis (RA). With the development and wider use of highly effective disease modifying…
Abstract Number: 448 • 2017 ACR/ARHP Annual Meeting
Predicting Remission at 6 Months in Early Rheumatoid Arthritis Treated with Conventional Synthetic Dmards
Michael D Wiese¹, Robert Metcalf², Mihir D Wechalekar³, Llew Spargo², Leah McWilliams⁴, Michael James^4,5, Catherine Hill⁶ and Susanna Proudman⁷, ¹School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia, ²Rheumatology Unit, Royal Adelaide Hospital, South Australia, Adelaide, Australia, ³Royal Adelaide Hospital, Adelaide, Australia, ⁴Department of Rheumatology, Royal Adelaide Hospital, Adelaide, Australia, ⁵Department of Medicine, University of Adelaide, Adelaide, Australia, ⁶The Queen Elizabeth Hospital, Adelaide, Australia, ⁷University of Adelaide, Adelaide, Australia
Background/Purpose: Initial treatment of RA with triple csDMARD therapy can achieve remission in a proportion of patients. Others respond poorly yet must wait at least…

1
2
3
…
8
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].